Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]
Read More
Rosemary Foster, PhDMassachusetts General Hospital Identification and Characterization of the Ovarian Cancer Stem Cell Cancer stem cells have recently been identified in some solid tumors and are thought to drive tumor formation. Most tumors likely contain rare subpopulations of stem-like cells that would serve as critical targets of more clinically effective therapies. Our research experiments […]
Read More
Elda Righi, MDMassachusetts General Hospital Blockade of the CXCL12 and VEGF axes in ovarian cancer One of the reasons ovarian cancer progresses with few evident symptoms may be the combination of ways in which the cancer escapes the patient’s immune system and organizes a vascular supply to serve its own needs. CXCL12 and VEGF are […]
Read More
Capucine Van Rechem, PhDMassachusetts General Hospital2014 Skacel Family Scholar Copy Gain and Resistance: Uncovering Roles for Epigenetic Regulation in Ovarian Cancer A major issue in the treatment of ovarian cancer is the development of resistance to standard chemotherapy. Such drug resistance has been linked to the gain of a specific genomic region, 1q12-1q21. Dr. Van […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
David Pepin, PhDMassachusetts General Hospital AAV9 gene therapy using a novel engineered MIS to treat ovarian cancer Ovarian cancer tumors are made up mostly of cells that respond well to chemotherapy, but a minority of stem-like cells survive treatment and ultimately lead to chemoresistant recurrence. However, this type of cancer stem cell is inhibited by […]
Read More
Mark Poznansky, MD, PhDMassachusetts General Hospital Antagonism of SDF-1 production by ovarian cancer and tumor immune control Immune cell migration into ovarian cancer is an important way in which the tumor is recognized as abnormal and killed by the immune system. Ovarian cancer tumors produce high amounts of a protein called SDF-1, thereby preventing immune […]
Read More